Found: 892
Select item for more details and to access through your institution.
Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 11, p. 2920, doi. 10.1111/bcp.16188
- By:
- Publication type:
- Article
Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy.
- Published in:
- Cancers, 2024, v. 16, n. 20, p. 3529, doi. 10.3390/cancers16203529
- By:
- Publication type:
- Article
Hyperprogression after nivolumab for the treatment of melanoma.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 4, p. 616, doi. 10.25259/IJDVL_160_2021
- By:
- Publication type:
- Article
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3065, doi. 10.1007/s00432-022-04206-8
- By:
- Publication type:
- Article
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3185, doi. 10.1007/s00432-022-04205-9
- By:
- Publication type:
- Article
Real world data on IO-based therapy for metastatic renal cell carcinoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3249, doi. 10.1007/s00432-022-04173-0
- By:
- Publication type:
- Article
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 12, p. 3537, doi. 10.1007/s00432-022-04055-5
- By:
- Publication type:
- Article
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 9, p. 2789, doi. 10.1007/s00432-021-03610-w
- By:
- Publication type:
- Article
Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma.
- Published in:
- Archives of Dermatological Research, 2022, v. 314, n. 9, p. 887, doi. 10.1007/s00403-021-02305-z
- By:
- Publication type:
- Article
Use of Cystatin C to Assess Immunotherapy Toxicity in a Patient With Melanoma.
- Published in:
- Journal of Pharmacy Practice, 2022, v. 35, n. 2, p. 308, doi. 10.1177/0897190020966201
- By:
- Publication type:
- Article
The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events.
- Published in:
- Journal of Pharmacy Practice, 2021, v. 34, n. 3, p. 386, doi. 10.1177/0897190019872937
- By:
- Publication type:
- Article
The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 58, doi. 10.14744/ejmi.2023.36214
- By:
- Publication type:
- Article
Rechallenge Immunotherapy in Former Interferon-Treated Patients with Metastatic Renal Cell Carcinoma.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 43, doi. 10.14744/ejmi.2023.11907
- By:
- Publication type:
- Article
Combined LDH Albumin Score (CLAS) and Neutrophil-Lymphocyte Ratio (NLR) are Predictive for Survival in Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 28, doi. 10.14744/ejmi.2023.21564
- By:
- Publication type:
- Article
Prognostic Effect of Psoas Muscle Index, a Parameter of Sarcopenia, in Solid Cancer Patients Receiving Immunotherapy.
- Published in:
- Eurasian Journal of Medical Investigation, 2023, v. 7, n. 4, p. 361, doi. 10.14744/ejmi.2023.30675
- By:
- Publication type:
- Article
Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 4, p. 429, doi. 10.14744/ejmi.2022.79013
- By:
- Publication type:
- Article
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 6, p. 14
- Publication type:
- Article
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 6, p. 1
- By:
- Publication type:
- Article
Novel LAG-3-Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 4, p. 9
- By:
- Publication type:
- Article
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 4, p. 11
- By:
- Publication type:
- Article
SC Nivolumab Could Reduce Disparities in the Care of Patients With Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncology Practice Management, 2024, v. 14, n. 4, p. 18
- Publication type:
- Article
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 1
- By:
- Publication type:
- Article
First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 30
- Publication type:
- Article
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 16
- By:
- Publication type:
- Article
Pilot Study Shows Clinical Benefit with Nivolumab in Pediatric Patients with Hypermutant Cancers.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 12, p. 30
- By:
- Publication type:
- Article
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 9, p. 17
- By:
- Publication type:
- Article
Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 10, p. 37
- Publication type:
- Article
Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis.
- Published in:
- Journal of Cosmetic Dermatology, 2024, v. 23, n. 4, p. 1165, doi. 10.1111/jocd.16105
- By:
- Publication type:
- Article
Nivolumab‐induced plaque morphea in a malign melanoma patient.
- Published in:
- Journal of Cosmetic Dermatology, 2021, v. 20, n. 8, p. 2645, doi. 10.1111/jocd.13914
- By:
- Publication type:
- Article
Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer.
- Published in:
- Journal of Cancer Research & Practice, 2024, v. 11, n. 2, p. 81, doi. 10.4103/ejcrp.eJCRP-D-23-00025
- By:
- Publication type:
- Article
Multiple immunosuppressants for immune-related acholia in a patient with metastatic colorectal cancer.
- Published in:
- Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 38, doi. 10.4103/ejcrp.eJCRP-D-22-00026
- By:
- Publication type:
- Article
Triad of myasthenia gravis, myositis, and myocarditis after nivolumab administration in a patient with cholangiocarcinoma.
- Published in:
- Journal of Cancer Research & Practice, 2022, v. 9, n. 4, p. 153, doi. 10.4103/2311-3006.362636
- By:
- Publication type:
- Article
Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinoma.
- Published in:
- Journal of Cancer Research & Practice, 2022, v. 9, n. 4, p. 145, doi. 10.4103/2311-3006.362634
- By:
- Publication type:
- Article
Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient.
- Published in:
- Neurological Sciences, 2021, v. 42, n. 12, p. 5377, doi. 10.1007/s10072-021-05557-9
- By:
- Publication type:
- Article
Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma.
- Published in:
- Central European Journal of Immunology, 2023, v. 48, n. 3, p. 251, doi. 10.5114/ceji.2023.130864
- By:
- Publication type:
- Article
Nivolumab in two cases of refractory mycosis fungoides erythroderma.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2023, v. 27, p. 86
- By:
- Publication type:
- Article
Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2022, v. 26, n. 3, p. 957
- By:
- Publication type:
- Article
Giant cell arteritis and therapeutic response: a dual facet of immunotherapy in metastatic clear cell renal carcinoma.
- Published in:
- Oxford Medical Case Reports, 2024, v. 2024, n. 7, p. 1, doi. 10.1093/omcr/omae082
- By:
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐144: Prognostic value of neutrophil‐to‐lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab.
- Published in:
- Respirology, 2021, v. 26, p. 344, doi. 10.1111/resp.14150_656
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article
P8‐136: Nivolumab for malignant mesothelioma: A real‐word experience.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_648
- Publication type:
- Article
P8‐119: An autopsy case of immune‐related severe colitis consequent to long‐term treatment with nivolumab in a patient with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 334, doi. 10.1111/resp.14150_631
- Publication type:
- Article
P8‐104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum‐based chemotherapy, single‐center, retrospective analysis.
- Published in:
- Respirology, 2021, v. 26, p. 329, doi. 10.1111/resp.14150_616
- Publication type:
- Article
P8‐82: CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 319, doi. 10.1111/resp.14150_594
- Publication type:
- Article
P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_546
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article
P8‐136: Nivolumab for malignant mesothelioma: A real‐word experience.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_648
- Publication type:
- Article